GANX earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -3.17. Updated 2026-07-23.
Gain Therapeutics (GANX) Research Hub
Gain Therapeutics (GANX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.75 USD (+1.74%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.17, market cap 0.08B. This hub links to the full technical, earnings and options research available for GANX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.75 USD (+1.74%) |
| 52-week range | 1.59 USD – 2.37 USD |
| Trend regime | Range |
| 14-day RSI | 46.7 (Neutral) |
| Trailing P/E | -3.17 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for GANX
Covered Call on GANX: how it works, illustrative setup around the real 1.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GANX: how it works, illustrative setup around the real 1.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GANX: how it works, illustrative setup around the real 1.75 USD price, max profit/loss, breakeven and when to use it. Educational.
GANX technical analysis: range, last 1.75 USD, RSI 46.7, 52w range 1.59 USD–2.37 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GANX in?
Gain Therapeutics (GANX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GANX in an uptrend or downtrend?
As of 2026-09-11, GANX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GANX's trailing P/E ratio?
GANX's trailing P/E is -3.17, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does GANX next report earnings?
GANX is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.14 USD.